| Literature DB >> 29860590 |
Janina Kluge1, Dominik Terfehr1, Ulrich Kück2.
Abstract
In industry, filamentous fungi have a prominent position as producers of economically relevant primary or secondary metabolites. Particularly, the advent of genetic engineering of filamentous fungi has led to a growing number of molecular tools to adopt filamentous fungi for biotechnical applications. Here, we summarize recent developments in fungal biology, where fungal host systems were genetically manipulated for optimal industrial applications. Firstly, available inducible promoter systems depending on carbon sources are mentioned together with various adaptations of the Tet-Off and Tet-On systems for use in different industrial fungal host systems. Subsequently, we summarize representative examples, where diverse expression systems were used for the production of heterologous products, including proteins from mammalian systems. In addition, the progressing usage of genomics and functional genomics data for strain improvement strategies are addressed, for the identification of biosynthesis genes and their related metabolic pathways. Functional genomic data are further used to decipher genomic differences between wild-type and high-production strains, in order to optimize endogenous metabolic pathways that lead to the synthesis of pharmaceutically relevant end products. Lastly, we discuss how molecular data sets can be used to modify products for optimized applications.Entities:
Keywords: Functional genomics; Fungal biotechnology; Heterologous products; Inducible promoter systems; Strain improvement
Mesh:
Year: 2018 PMID: 29860590 PMCID: PMC6061484 DOI: 10.1007/s00253-018-9115-1
Source DB: PubMed Journal: Appl Microbiol Biotechnol ISSN: 0175-7598 Impact factor: 4.813
Inducible promoters in filamentous fungi
| Promoter | Gene product | Induction by/repression by | Donor | Reference |
|---|---|---|---|---|
|
| Alcohol dehydrogenase I | Ethanol/glucose |
| Waring et al. ( |
|
| TAKA-amylase A | Starch or maltose/glucose |
| Tada et al. ( |
|
| Blue light-inducible gene | Blue light/darkness |
| Eberle and Russo ( |
|
| Benzoate p-hydrolase | Benzoic acid (benzoate)/deficiency of benzoate |
| Antunes et al. ( |
|
| Catalase | H2O2 and CaCO3/n.d. |
| Sharma et al. ( |
|
| Cellobiohydrolase I | Various saccharides/glucose |
| Nyyssönen and Keränen ( |
|
| Glucose repressor | Glucose/deficiency of glucose |
| Janus et al. ( |
|
| Endoxylanase | Xylose/sucrose |
| Gouka et al. ( |
|
| 1,3-beta-glucanosyltransferase | Low pH value/pH > 5.0 |
| Yin et al. ( |
|
| Glucoamylase A | Glucose/xylose |
| Boel et al. ( |
|
| Glucoamylase | Glucose/xylose |
| Bulakhov et al. ( |
|
| Siderophore transporter | Iron starvation/Iron sufficiency |
| Gsaller et al. ( |
|
| Nitrite reductase | Nitrate/ammonium |
| Müller et al. ( |
|
| Catabolic 3-dehydroquinase | Quinic acid/low quinic acid or high sugar concentration |
| Giles et al. ( |
|
| Endoxylanase | Xylose/glucose |
| Bloemendal et al. ( |
|
| Copper transporter | Copper depletion/copper availability |
| Lamb et al. ( |
|
| Thiamine thiazole synthase | Thiamine/deficiency of thiamine |
| Shoji et al. ( |
|
| Blue light receptor | Light/darkness |
| Hurley et al. ( |
|
| Endoxylanase | Xylose (and xylan)/glucose |
| Blatzer et al. ( |
|
| Endoxylanase | Xylose (and xylan)/glucose |
| Zadra et al. ( |
|
| Endoxylanase | Low concentration of xylose/high concentration of xylose |
| Mach et al. ( |
|
| Transcription factor | Zearalenone/Deficiency of zearalenone |
| Lee et al. ( |
Fig. 1Tet-Off expression system. a Basic version of the Tet-Off expression system in eukaryotes. The fusion of TetR with VP16 leads to the generation of the tetracyclin-dependent transactivator tTA. When tetracycline or its analog doxycycline is added, tTA is unable to specifically bind to tetO due to a conformational change. As a result, transcription of the gene of interest, which is controlled by Pmin, is disrupted. Thus, transcriptional activation takes place in the absence of tetracycline or doxycycline. Addition of the either drug leads to transcriptional shutdown. Dox, doxycycline; VP16, transcriptional activator domain from herpes simplex virus; tc, tetracycline; TetR, tetracycline-dependent Tet repressor; tetO; tetracycline operator sequence; tTA, tetracyclin-dependent transactivator; TtrpC, trpC terminator from Aspergillus nidulans; Pmin, minimal promoter. b Optimized module of the Tet-Off expression system for A. niger. The transactivator tTA2S, optimized for mammals, was used downstream of PgpdA promoter. The promoter can be selected individually depending on the model organism (PgeneX). Seven copies of tetO sequence were inserted (tetO7) upstream of a minimal promoter in order to increase tTA2S binding. In the absence of tetracycline or its analog doxycycline tTA2S is able to specifically bind tetO7. Thus, the transcriptional induction of the gene of interest, which is controlled by Pmin takes place. Addition of drug leads to transcriptional shutdown. For further details, see text. Abbreviations: Dox, doxycycline; VP16, transcriptional activator domain from herpes simplex virus tc, tetracycline; TetR, tetracycline-dependent Tet repressor; tetO, tetracycline operator sequence; tetO7, seven copies of tetracycline operator sequence; tTA, tetracyclin-dependent transactivator; tTA2S, mammalian tetracyclin-dependent transactivator; TcrgA, crgA terminator from Aspergillus fumigatus; TtrpC, trpC terminator from Aspergillus nidulans; Pmin, minimal promoter (adopted from Brockamp et al. 2002, Wanka et al. 2016)
Fig. 2Tet-On expression system. a Basic version of the Tet-On expression system in eukaryotes. The rtTA fusion protein comprises of TetR and VP16 activation domain. A four amino acid change in the TetR DNA binding motif alters rtTA’s binding characteristics, such that it can only recognize tetO sequence in the presence of tetracycline or its analog doxycycline. Thus transcriptional induction of the gene of interest, which is controlled by a minimal promoter, takes place. b Optimized version of the Tet-On expression system for A. niger. The insertion of additional mutations resulted in the reverse hybrid transactivator rtTA2S-M2, which is controlled by the PgpdA promoter, to increase the rtTA binding sensitivity and the expression level of rtTA. The used promoter can be selected individually depending on the model organism (PgeneX). An improvement of tetO was achieved by the insertion of seven copies of tetO sequence (tetO7) upstream of the minimal promoter. In the presence of tetracycline or its analog doxycycline, rtTA2S-M2 is able to specifically bind tetO7 in order to induce the transcription of the selected gene of interest. For further details, see text. Abbreviations: rtTA2S-M2, mutated reverse hybrid transactivator. All other abbreviations are given in the legend of Fig. 1. (adopted from Brockamp et al. 2002, Wanka et al. 2016)